Results 31 to 40 of about 760 (154)

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant \u3ci\u3eAcinetobacter baumannii\u3c/i\u3e Infections [PDF]

, 2023
OBJECTIVE: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant DATA SOURCES: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam ...
Kale-Pradhan, Pramodini B, Matlob, Andrew, August, Benjamin A   +2 more
core  

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms. [PDF]

J Antimicrob Chemother
BACKGROUND: Acinetobacter baumannii is a nosocomial pathogen known for rapidly developing resistance to nearly all antibiotics, including last-line agents. Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against A.
Halim J, Keane AP, Bouzo J, Aderibigbe T, Chicola JA, Nolan KT, Jonnalagadda K, Tran JX, Carabetta VJ.   +8 more
europepmc   +2 more sources

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp ...
Harald Seifert, Carina Müller, Danuta Stefanik, Paul G Higgins, Alita Miller, Michael Kresken   +5 more
openaire   +2 more sources

Turning the Tide Against Carbapenem-resistant <i>Acinetobacter baumannii</i>: Advancing Care With Sulbactam-Durlobactam. [PDF]

Open Forum Infect Dis
Satlin M, Shields RK, Torres A, Tillotson G.   +3 more
europepmc   +3 more sources

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy, 2020
AbstractBackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii.
Harald Reinhart, Patricia A Bradford, Meredith Hackel, Jun Deng, Ge Zhang, Jingjia Zhang, Ying Zhu, Peiyao Jia, Yingchun Xu, Qiwen Yang   +9 more
openaire   +2 more sources

Durlobactam in combination with β-lactams to combat Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy
ABSTRACT Mycobacterium abscessus ( Mab ) presents significant clinical challenges. This study evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against Mab and explored the underlying mechanisms ...
Eunjeong Shin, Khalid M. Dousa, Magdalena A. Taracila, Christopher R. Bethel, Mary Nantongo, David C. Nguyen, Chidiebere Akusobi, Sebastian G. Kurz, Mark S. Plummer, Charles L. Daley, Steven M. Holland, Eric J. Rubin, Jürgen B. Bulitta, W. Henry Boom, Barry N. Kreiswirth, Robert A. Bonomo   +15 more
openaire   +2 more sources

Μελέτη νεότερου αναστολέα β-λακταμασών σε ανθεκτικά στις καρβαπενέμες στελέχη Acinetobacter baumannii [PDF]

, 2022
ΕΙΣΑΓΩΓΗ: Το Acinetobacter baumannii αποτελεί κύρια αιτία λοιμώξεων σχετιζόμενων με χώρους υγειονομικής περίθαλψης, εξαιτίας της επιμονής του ως αποικιστή στο νοσοκομειακό περιβάλλον και της ικανότητας του να αποκτά υψηλού επιπέδου αντοχή.
Petropoulou Dimitra, Πετροπούλου Δήμητρα   +1 more
core  

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates [PDF]

: We evaluated in vitro activity of sulbactam/durlobactam in combination with different antimicrobials against Carbapenem-Resistant Acinetobacter baumannii (CRAB) clinical isolates with different susceptibility profiles, including sulbactam/durlobactam ...
Zocche, Giulia, Lewis, Russell E, Tascini, Carlo, Gaibani, Paolo, Bianco, Gabriele   +4 more
core   +1 more source

Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives [PDF]

, 2023
Purpose of review Serious infections caused by nonfermenting Gram-negative bacteria (NF-GNB) pose a significant challenge for clinicians due to the limited treatment options available, which are frequently associated with issues of toxicity and ...
Daniele Roberto Giacobbe, Alberto Fantin, Matteo Bassetti, Castaldo, Nadia, Fantin, Alberto, Nadia Castaldo, Vena, Antonio, Bassetti, Matteo, Antonio Vena, Giacobbe, Daniele Roberto   +9 more
core   +1 more source